CRANBURY, N.J., Sept. 25 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. will announce its fourth quarter and fiscal year end 2008 financial results on September 30, 2008 before the open of the U.S. financial markets.
The Company will also conduct a conference call and live audio webcast hosted by Palatin’s executive management team on September 30, 2008 at which they will discuss the results of operations in greater detail and provide an update on corporate developments.
Schedule for the Financial Results Press Release, Conference Call and Webcast
The webcast and replay can be accessed by logging on to the “Investor Center-Webcasts” section of Palatin’s website at www.palatin.com.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies’ website at http://www.palatin.com.
Forward-looking Statements
Statements about the Company’s future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements shall be subject to the safe harbors created thereby. Palatin’s actual results may differ materially from those discussed in the forward- looking statements for various reasons, including, but not limited to the Company’s ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to protect its intellectual property, and other factors discussed in the Company’s periodic filings with the Securities and Exchange Commission. The Company is not responsible for updating for events that occur after the date of this press release.
CONTACT: For Palatin Technologies, Stephen T. Wills, CPA, MST,
EVP-Operations and Chief Financial Officer, +1-609-495-2200,
info@palatin.com; or for Institutional Investors and Media: Susan Kim,
Burns McClellan, +1-212-213-0006, skim@burnsmc.com
Web site: http://www.palatin.com/
